Verition Fund Management LLC Purchases Shares of 62,501 Ocular Therapeutix, Inc. (NASDAQ:OCUL)

Verition Fund Management LLC purchased a new position in Ocular Therapeutix, Inc. (NASDAQ:OCUL - Free Report) in the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The firm purchased 62,501 shares of the biopharmaceutical company's stock, valued at approximately $544,000.

A number of other large investors also recently bought and sold shares of OCUL. Atlas Capital Advisors LLC bought a new stake in Ocular Therapeutix in the second quarter worth $34,000. Amalgamated Bank raised its position in shares of Ocular Therapeutix by 37.9% in the 2nd quarter. Amalgamated Bank now owns 5,384 shares of the biopharmaceutical company's stock worth $37,000 after purchasing an additional 1,481 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. boosted its stake in Ocular Therapeutix by 22.0% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 5,639 shares of the biopharmaceutical company's stock worth $49,000 after purchasing an additional 1,015 shares in the last quarter. Algert Global LLC purchased a new stake in Ocular Therapeutix during the 2nd quarter valued at about $69,000. Finally, Capital Performance Advisors LLP bought a new stake in Ocular Therapeutix during the 3rd quarter valued at about $70,000. 59.21% of the stock is owned by hedge funds and other institutional investors.

Insider Transactions at Ocular Therapeutix

In other news, insider Jeffrey S. Heier sold 2,948 shares of the stock in a transaction that occurred on Monday, November 25th. The shares were sold at an average price of $9.01, for a total value of $26,561.48. Following the transaction, the insider now owns 269,059 shares in the company, valued at $2,424,221.59. This represents a 1.08 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Company insiders own 3.50% of the company's stock.

Analyst Upgrades and Downgrades

Several brokerages have recently issued reports on OCUL. HC Wainwright reiterated a "buy" rating and issued a $15.00 target price on shares of Ocular Therapeutix in a research note on Tuesday, December 3rd. Scotiabank assumed coverage on Ocular Therapeutix in a research note on Wednesday, October 16th. They set a "sector outperform" rating and a $22.00 target price on the stock. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and six have given a buy rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of $16.71.

Ocular Therapeutix Stock Performance

NASDAQ:OCUL traded down $0.67 during trading hours on Thursday, reaching $8.89. The company had a trading volume of 1,101,837 shares, compared to its average volume of 1,791,441. The firm has a market cap of $1.40 billion, a price-to-earnings ratio of -6.73 and a beta of 1.19. The company has a current ratio of 13.01, a quick ratio of 12.94 and a debt-to-equity ratio of 0.19. The firm's 50 day moving average price is $10.08 and its 200-day moving average price is $8.46. Ocular Therapeutix, Inc. has a 52 week low of $3.24 and a 52 week high of $11.77.

Ocular Therapeutix Company Profile

Ocular Therapeutix, Inc, a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis.